Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Recordati has announced the completion of the mutual recognition process for the approval throughout the EU, in Norway and in Iceland, of its new antihypertensive specialty based on a fixed combination of lercanidipine and enalapril.
Subscribe to our email newsletter
Germany acted as reference member state and the 28 concerned member states decided to recognize the approval granted in 2006 by the German medicines agency (BfArM) of this new product in its two dosage forms containing lercanidipine 10mg/enalapril 10mg and lercanidipine 10mg/enalapril 20mg. The product is already on the market in Germany as from 2007.
Giovanni Recordati, chairman and CEO of Recordati, said: “We will initiate launches in all these countries, in which lercanidipine has already obtained the physicians’s appreciation, gradually as from the second half of the year. The new product will be sold directly by our marketing organizations in most of the European pharmaceutical market.”